 Merck  Cos drug Zetia proved effective at reducing risk of heart attacks strokes and other heart problems in a large longawaited trial marking a milestone in the yearold battle to fight cardiovascular disease by lowering cholesterol The benefit was modesta  reduction in all cardiovascular events in a highrisk aggressively treated population of patients But it was the first time that adding a nonstatin cholesterol fighter to the blockbuster statin class of cholesterollowering medicines was shown to
  